Cargando…

Angiotensin II Receptor Blockers in the Management of Hypertension in Preventing Cognitive Impairment and Dementia—A Systematic Review

Hypertension is a known risk factor for cognition-related pathologies including dementia. The National Institute of Health and Care Excellence (NICE) guidelines recommend angiotensin (Ang) II receptor blockers (ARBs) or angiotensin-converting enzyme inhibitors (ACEIs) as a first-line treatment for h...

Descripción completa

Detalles Bibliográficos
Autores principales:	D’Silva, Elvira, Meor Azlan, Nur Farah, Zhang, Jinwei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Systematic Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9609033/ https://www.ncbi.nlm.nih.gov/pubmed/36297558 http://dx.doi.org/10.3390/pharmaceutics14102123

Ejemplares similares

Regulatory control of the Na–Cl co-transporter NCC and its therapeutic potential for hypertension
por: Meor Azlan, Nur Farah, et al.
Publicado: (2021)

Role of the Cation-Chloride-Cotransporters in Cardiovascular Disease
por: Meor Azlan, Nur Farah, et al.
Publicado: (2020)

COVID-19 and the Use of Angiotensin II Receptor Blockers in Older Chronic Hypertensive Patients: Systematic Review and Meta-Analysis
por: Quesada-Caballero, Miguel, et al.
Publicado: (2023)

The use of angiotensin receptor blockers in dementia prevention
por: Müller, Jordana de Araujo, et al.
Publicado: (2023)

Targeting the WNK-SPAK/OSR1 Pathway and Cation-Chloride Cotransporters for the Therapy of Stroke
por: Josiah, Sunday Solomon, et al.
Publicado: (2021)

Usage of Angiotensin-Converting Enzyme Inhibitor or Angiotensin II Receptor Blocker in Hypertension Intracerebral Hemorrhage
por: Zhang, Chao, et al.
Publicado: (2021)

Role of the cation-chloride-cotransporters in the circadian system
por: Salihu, Shihan, et al.
Publicado: (2021)

Angiotensin II receptor blockers in the prevention of complications from atrial fibrillation
por: Naccarelli, Gerald V, et al.
Publicado: (2009)

Angiotensin receptor blocker add-on therapy in portal hypertension: To use angiotensin receptor blocker or not to use, that is the question
por: Lee, Hyun Woong
Publicado: (2014)

Visit-to-Visit Variability and Seasonal Variation in Blood Pressure With Single-Pill Fixed-Dose Combinations of Angiotensin II Receptor Blocker/Calcium Channel Blocker and Angiotensin II Receptor Blocker/Diuretic in Hypertensive Patients
por: Shiga, Yuhei, et al.
Publicado: (2015)

Calcium channel blockers, angiotensin receptor blockers, and angiotensin-converting enzyme inhibitors: Effectiveness in combination with diuretics or β-blockers for treating hypertension
por: Bisognano, John D, et al.
Publicado: (2007)

Evaluation of the angiotensin II receptor blocker azilsartan medoxomil in African‐American patients with hypertension
por: Johnson, Wallace, et al.
Publicado: (2017)

Anticholinergic drugs and incident dementia, mild cognitive impairment and cognitive decline: a meta-analysis
por: Pieper, Nina T, et al.
Publicado: (2020)

Roles of Brain Angiotensin II in Cognitive Function and Dementia
por: Mogi, Masaki, et al.
Publicado: (2012)

An angiotensin II receptor blocker–calcium channel blocker combination prevents cardiovascular events in elderly high-risk hypertensive patients with chronic kidney disease better than high-dose angiotensin II receptor blockade alone
por: Kim-Mitsuyama, Shokei, et al.
Publicado: (2013)

Impact of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in Hypertensive Patients with COVID-19 (COVIDECA Study)
por: Mustafic, Hazrije, et al.
Publicado: (2021)

Risk of Mild Cognitive Impairment or Probable Dementia in New Users of Angiotensin II Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors: A Secondary Analysis of Data From the Systolic Blood Pressure Intervention Trial (SPRINT)
por: Cohen, Jordana B., et al.
Publicado: (2022)

Incidence and Pattern of Aminotransferase Elevation During Anti-Hypertensive Therapy With Angiotensin-II Receptor Blockers
por: Choi, Won Joon, et al.
Publicado: (2022)

Why angiotensin converting enzyme inhibitors and angiotensin II receptor blockers are not prescribed in the management of hypertension among hemodialysis patients in India
por: Mateti, Uday Venkat, et al.
Publicado: (2014)

The association of COVID-19 occurrence and severity with the use of angiotensin converting enzyme inhibitors or angiotensin-II receptor blockers in patients with hypertension
por: Li, Mingfei, et al.
Publicado: (2021)

Association between Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers and Mortality in Patients with Hypertension Hospitalized with COVID-19
por: Abedtash, Amirhossein, et al.
Publicado: (2021)

Angiotensin II Receptor Blockers and Arrhythmias in Ventricular Hypertrophy
por: Salama, Guy
Publicado: (2022)

Clinical Pharmacogenetics of Angiotensin II Receptor Blockers in Iraq
por: Al-Hussaniy, Hany A., et al.
Publicado: (2023)

The Fetal Safety of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers
por: Moretti, Myla E., et al.
Publicado: (2012)

Receptor Interactions of Angiotensin II and Angiotensin Receptor Blockers—Relevance to COVID-19
por: Moore, Graham J., et al.
Publicado: (2021)

Combining angiotensin receptor blockers with chlorthalidone or hydrochlorothiazide – which is the better alternative? A meta-analysis
por: Filipova, Elena, et al.
Publicado: (2020)

Efficacy and Safety of Combination Therapy Consisting of Angiotensin II Type 1 Receptor Blocker, Calcium Channel Blocker and Hydrochlorothiazide in Patients With Hypertension
por: Shiga, Yuhei, et al.
Publicado: (2017)

Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors in COVID-19: Meta-analysis/Meta-regression Adjusted for Confounding Factors
por: Lee, Terry, et al.
Publicado: (2021)

Angiotensin Receptor Blocker and Calcium Channel Blocker Preventing Atrial Fibrillation Recurrence in Patients with Hypertension and Atrial Fibrillation: A Meta-analysis
por: Ma, Haotian, et al.
Publicado: (2021)

Valsartan vs. other angiotensin II receptor blockers in the treatment of hypertension: a meta-analytical approach
por: Nixon, R M, et al.
Publicado: (2009)

Effects of candesartan, an angiotensin II receptor type I blocker, on atrial remodeling in spontaneously hypertensive rats
por: Choisy, Stéphanie C., et al.
Publicado: (2015)

Effects of L-/N-Type Calcium Channel Blockers on Angiotensin II–Renin Feedback in Hypertensive Patients
por: Kawabata, Yutaka, et al.
Publicado: (2020)

What Are the Neural Correlates of Impaired Awareness of Social Cognition and Function in Dementia? A Systematic Review
por: Hengstschläger, Anna, et al.
Publicado: (2022)

A combined role of calcium channel blockers and angiotensin receptor blockers in stroke prevention
por: Wang, Ji-Guang
Publicado: (2009)

Comparative effect of angiotensin II type I receptor blockers and calcium channel blockers on laboratory parameters in hypertensive patients with type 2 diabetes
por: Nishida, Yayoi, et al.
Publicado: (2012)

Effect of Switching to Azilsartan From Fixed-Dose Combination of an Angiotensin II Receptor Blocker and Calcium Channel Blocker or a Thiazide in Patients With Hypertension
por: Miyoshi, Toru, et al.
Publicado: (2019)

The current practice of using angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in diabetic hypertensive and non-hypertensive patients: Is there a room for vitamin D?
por: Sukkarieh, Hatouf H., et al.
Publicado: (2020)

Pneumonia Risk and Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers
por: Liu, Chia-Lin, et al.
Publicado: (2013)

Effect of angiotensin converting enzyme inhibitor and angiotensin II receptor blocker on the patients with sepsis
por: Lee, Hyun Woo, et al.
Publicado: (2021)

Fracture Risk and Use of Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers
por: Holloway-Kew, Kara L., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_30jkorronrk503bciir9i38d58